<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964182</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0638</org_study_id>
    <secondary_id>NCI-2019-02501</secondary_id>
    <secondary_id>2015-0638</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>R01DA042526</secondary_id>
    <nct_id>NCT02964182</nct_id>
  </id_info>
  <brief_title>Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers</brief_title>
  <official_title>Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E-Cigarettes Among Daily and Non-Daily Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well different levels of nicotine in very low nicotine content&#xD;
      cigarettes and electronic cigarettes (e-cigarettes) work in promoting smoking cessation in&#xD;
      current daily and intermittent smokers. Different levels of nicotine may effect certain&#xD;
      behaviors, including withdrawal symptoms, nicotine cravings, and mood and may lead to changes&#xD;
      in smoking behavior, including finding it easier to quit smoking, in current daily and&#xD;
      intermittent smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To characterize the effects of dual use of very low nicotine content cigarettes (VLNCC)&#xD;
      and electronic cigarettes (ECIG) on abuse liability (nicotine compensation and product use,&#xD;
      liking, and relative reinforcing efficacy [RRE]) and toxicant exposure among daily (DS)&#xD;
      smokers.&#xD;
&#xD;
      II. To characterize the effects of dual use of VLNCC and ECIG on abuse liability (nicotine&#xD;
      compensation and product use, liking, and RRE) and toxicant exposure among intermittent (ITS)&#xD;
      smokers.&#xD;
&#xD;
      III. To characterize the effects of dual product use on abuse liability using measure of&#xD;
      withdrawal, craving, affect, and satisfaction (reinforcement).&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To characterize the effects of dual use of VLNCC and JUUL ECIG on abuse liability&#xD;
      (nicotine compensation and product use, liking, and RRE) and toxicant exposure among daily&#xD;
      (DS) smokers.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      PHASE I: Patients smoke their usual cigarettes brand during week 1.&#xD;
&#xD;
      PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.&#xD;
&#xD;
      PHASES III-IV: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients smoke ECIG-high (Hi) for 3 weeks and then ECIG-low (Lo) for 3 weeks&#xD;
&#xD;
      ARM II: Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks.&#xD;
&#xD;
      After completion of study, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of dual use of very low nicotine content cigarettes (VLNCC) and e-cigarettes (ECIG) on nicotine abuse liability among daily smokers (DS)</measure>
    <time_frame>10 weeks</time_frame>
    <description>Measured by number of VLNCC cigarettes per day and the number of puffs of eCigarette use per day in the DS group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of dual use of VLNCC and ECIG on nicotine abuse liability among intermittent smokers</measure>
    <time_frame>10 weeks</time_frame>
    <description>Measured by number of VLNCC cigarettes per day and the number of puffs of eCigarette use per day in the ITS group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Cigarette Smoker</condition>
  <condition>Current Every Day Smoker</condition>
  <condition>Current Non-Daily or Intermittent Smoker</condition>
  <arm_group>
    <arm_group_label>Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHASE I: Patients smoke their usual cigarettes brand during week 1.&#xD;
PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.&#xD;
PHASES III-IV: Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHASE I: Patients smoke their usual cigarettes brand during week 1.&#xD;
PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.&#xD;
PHASES III-IV: Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cigarette</intervention_name>
    <description>Smoke usual brand of cigarettes</description>
    <arm_group_label>Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
    <arm_group_label>Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Cigarette</intervention_name>
    <description>Smoke ECIG-Hi</description>
    <arm_group_label>Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
    <arm_group_label>Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
    <other_name>e-Cigarette</other_name>
    <other_name>Electronic Nicotine Delivery System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Cigarette</intervention_name>
    <description>Smoke ECIG-Lo</description>
    <arm_group_label>Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
    <arm_group_label>Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
    <other_name>e-Cigarette</other_name>
    <other_name>Electronic Nicotine Delivery System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
    <arm_group_label>Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
    <arm_group_label>Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Very Low Nicotine Content Cigarette</intervention_name>
    <description>Smoke very low nicotine content cigarette</description>
    <arm_group_label>Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
    <arm_group_label>Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)</arm_group_label>
    <other_name>VLNCC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign consent and agree to all study procedures&#xD;
&#xD;
          -  Have a telephone and address where they may be reached&#xD;
&#xD;
          -  Able to follow verbal and written instructions in English&#xD;
&#xD;
          -  Be the only participant in their household&#xD;
&#xD;
          -  Interested in trying novel nicotine products&#xD;
&#xD;
          -  Daily smokers: &gt;= 1 cigarette/little cigar per day&#xD;
&#xD;
          -  Intermittent smokers: &gt;= 1 cigarette/little cigar per day 4 to 27 days per month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling to refrain from other e-cigarette use for the duration of the study, other&#xD;
             than what is provided to them for study purposes&#xD;
&#xD;
          -  Positive urine screen for illicit drugs except marijuana&#xD;
&#xD;
               -  Participants with valid prescriptions for opiates, benzodiazepines, barbiturates,&#xD;
                  amphetamines or methadone will not be excluded&#xD;
&#xD;
               -  Participants failing the urine drug screen (except marijuana which is not&#xD;
                  exclusionary) will be allowed to re-screen once. If they test positive again,&#xD;
                  they will not be allowed to return)&#xD;
&#xD;
          -  Current/recent use of certain medications:&#xD;
&#xD;
               -  Smoking cessation meds (past 90 days; e.g., wellbutrin, bupropion, Zyban,&#xD;
                  nicotine replacement therapy [NRT], Chantix)&#xD;
&#xD;
               -  Certain medications to treat depression (last 14 days; e.g., amitriptyline)&#xD;
&#xD;
               -  A case by case determination will be made by study physician for medication on&#xD;
                  the precautionary list, (e.g. nitroglycerin)&#xD;
&#xD;
               -  Daily use of opioids for 30 days or more on phone screen or at screening is&#xD;
                  exclusionary however pro re nata (PRN) use is allowed (e.g., 3 to 7 days per week&#xD;
                  or less or if more frequent, use less than a month's duration&#xD;
&#xD;
          -  Unstable medical condition as determined by the medical team&#xD;
&#xD;
          -  Bronchial or respiratory infection in the last 14 days&#xD;
&#xD;
          -  Subject's spirometry forced expiratory volume in 1 second (FEV1) percentage reading is&#xD;
             &lt; 50 (severe to very severe obstruction)&#xD;
&#xD;
          -  Subject experienced abnormal heart rhythms or cardiovascular disease (stroke, chest&#xD;
             pain, heart attack) in the last 3 months&#xD;
&#xD;
          -  Subject's screening blood pressure reading &gt;= 180/110&#xD;
&#xD;
          -  Meet criteria for major depressive syndrome or suicidality on the Patient Health&#xD;
             Questionnaire-9 (PHQ-9)&#xD;
&#xD;
          -  Self report of past or current diagnosis of bi-polar disorder or&#xD;
             schizophrenia/schizoaffective disorder&#xD;
&#xD;
          -  Other tobacco use besides cigarettes or little cigars (e.g., hookah, cigarillos,&#xD;
             smokeless tobacco, chewing tobacco, pipes, cigars, etc.) on 10 or more days in the&#xD;
             last month&#xD;
&#xD;
          -  Recent (past 90 days), current, or planned (within the next 45 days) involvement in&#xD;
             smoking cessation activities&#xD;
&#xD;
          -  Positive urine pregnancy test at screening. Women who are two years post-menopausal,&#xD;
             or who have had a tubal ligation or a partial or full hysterectomy will not be subject&#xD;
             to a urine pregnancy test&#xD;
&#xD;
          -  Women that are breastfeeding or of childbearing potential and not protected by a&#xD;
             medically acceptable, effective method of birth control while enrolled in the study.&#xD;
             Medically acceptable contraceptives include:&#xD;
&#xD;
               -  Approved hormonal contraceptives (such as birth control pills, patches, implants&#xD;
                  or injections)&#xD;
&#xD;
               -  Barrier methods (such as condom or diaphragm) used with a spermicide, or&#xD;
&#xD;
               -  An intrauterine device (IUD)&#xD;
&#xD;
               -  Contraceptives sold for emergency use after unprotected sex are not acceptable&#xD;
                  methods for routine use&#xD;
&#xD;
          -  Subject considered by the investigator to be unsuitable to participate in the study&#xD;
             (e.g., due to cognitive deficits or instability to last the entire duration of the&#xD;
             study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Cinciripini</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Cinciripini, PHD, MS, BS</last_name>
    <phone>713-792-0919</phone>
    <email>pcinciri@mdanderson.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Ferguson</last_name>
    <phone>713-563-7018</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Cinciripini</last_name>
      <phone>713-792-0919</phone>
      <email>pcinciri@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Paul Cinciripini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>June 13, 2020</last_update_submitted>
  <last_update_submitted_qc>June 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

